Word

INVOLIN

Status

Dead

Status Code

710

Status Date

Friday, December 30, 2011

Serial Number

76307432

Registration Number

2954070

Registration Date

Tuesday, May 24, 2005

Mark Type

1000

Filing Date

Thursday, August 30, 2001

Published for Opposition

Tuesday, May 4, 2004

Cancellation Date

Friday, December 30, 2011

Trademark Owner History

CELLECTIS S.A. - Original Registrant

Classifications

1 chemical, biochemical, biotechnological products intended for industry, the sciences, agriculture, and horticulture, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research use; cells engineered by meganuclease recombination systems for scientific, laboratory or medical research; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research; deoxyribonucleic acid reagents for scientific research use, namely for the transport of biological molecules; microorganism cultures and preprations for use in the manufacture of human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; microorganisms used for producing therapeutic compounds or vaccines; microorganism cultures and preparations for medical research use, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for medical research use, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for use in the manufacture of human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of reagents and endocnuclease

5 Pharmaceutical, veterinary and health-care products, namely polypeptides for in vivo and in vitro genetic engineering for clinical use; natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease for clinical use; cells engineered by meganuclease recombination systems for clinical use; microorganism cultures and preparations for clinical medical use, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, and nucleic acid vectors; microorganism cultures and preparations for use as human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and microorganisms used for producing therapeutic compounds or vaccines; bacteriological preparations for clinical medical use, namely bacteriologic preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases and nucleic acid vectors; bacteriological preparations for use as human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; drugs for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; biological preparations for clinical medical use, namely polypeptides for in vivo in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemical biochemical preparations for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease, and cells engineered by meganuclease recombination systems; chemical and biochemical preparations for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemopharmaceutical products

42 Scientific and industrial research; research in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research in chemistry, biology, biochemistry, molecular biology, and bacteriology; research and development for others of techniques of biochemical analysis, biological analysis, and molecular biology techniques; scientific transgenesis research of deoxyribonucleic acid for the preparation or conveying of biological molecules; scientific analysis namely in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research and development for others of new molecules intended for industry; laboratory research in the fields of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; medical services; studies of technical projects in the field of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; testing, analysis and evaluation of engineering works for others; licensing of patents and intellectual property; computer programming for others, development for others of multimedia software programs

Trademark Events

Dec 30, 2011

Cancelled Sec. 8 (6-Yr)

May 24, 2005

Registered-Principal Register

Mar 25, 2005

Opposition Terminated No. 999999

Mar 25, 2005

Opposition Dismissed No. 999999

Sep 9, 2004

Opposition Instituted No. 999999

Jun 2, 2004

Extension Of Time To Oppose Received

May 4, 2004

Published For Opposition

Apr 14, 2004

Notice Of Publication

Feb 10, 2004

Approved For Pub - Principal Register

Oct 8, 2003

Correspondence Received In Law Office

Oct 18, 2003

Case File In Ticrs

Oct 8, 2003

Fax Received

Oct 3, 2003

Continuation Of Final Refusal Mailed

Sep 16, 2003

Previous Action Count Withdrawn

Sep 15, 2003

Previous Allowance Count Withdrawn

May 20, 2003

Approved For Pub - Principal Register

May 12, 2003

Correspondence Received In Law Office

May 7, 2003

Continuation Of Final Refusal Mailed

Mar 10, 2003

Correspondence Received In Law Office

Mar 10, 2003

Paper Received

Nov 15, 2002

Final Refusal Mailed

Nov 14, 2002

Sec. 1(B) Claim Deleted

Oct 8, 2002

Assigned To Examiner

May 6, 2002

Correspondence Received In Law Office

Nov 9, 2001

Non-Final Action Mailed

Nov 2, 2001

Assigned To Examiner